Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

letter

. 2024 Sep 28;23:210. doi: 10.1186/s12943-024-02123-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2024

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

PMC Copyright notice

Fig. 1 — A high percentage of CD16+ T cells positively predicts patient outcome. A) Percentages of CD16+ NK in aggressive B-NHL patients (patient, n = 46) at diagnosis compared to healthy controls (HC, n = 25). B) Kaplan-Meier survival curve over 24 months. Progression-free survival (PFS) for high (> 9.7%) and low (< 9.7%) percentages of CD16+ NK cells at diagnosis. C) Percentages of CD16+ T cells in aggressive B-NHL patients at diagnosis (patient, n = 46) compared to healthy controls (HC, n = 25). D) Kaplan-Meier survival curve over 24 months. PFS for high (> 1.6%) and low (< 1.6%) percentages of CD16+ T cells at diagnosis. E) Percentages of CD16+ T cells at diagnosis according to patient’s IPI (IPI 0–2, n = 25; IPI 3–5, n = 21). F) Cox proportional hazard analysis of high (> 1.6%) and low (< 1.6%) percentages of CD16+ T cells at diagnosis in relation to IPI over 24 months. G) Percentages of CD16+ T cells and CD16+ NK cells at diagnosis and during therapy, (the number of patients (n) for each population (in the order given on the x-axes) n = 46, 46, 26, 26, 22, 22). H) Representative lysis capacity of NK and T cell populations (below) of one patient concerning their respective percentages of CD16+ cells (above). NK and T cells were isolated and lysis capacity was measured using a population-based real-time killing assay. The shown effector to target cell ratio (E: T) is 2:1. Percentages of CD16+ cells within the NK and T cell populations were quantified by flow cytometry. I) Quantification of antibody-dependent cytotoxicity (ADCC) in relation to the percentage of CD16+ NK (NK, n = 22) or CD16+ T cells (T cell, n = 22) within the whole NK or CD3 + T cell population. ADCC capacity corresponds to the difference between the lysis of target cells with rituximab (+ RTX) and without rituximab (-RTX). J) Representative images of rituximab-dependent ADCC by sorted CD16+ NK and CD16+ T cells at single cell level against TMD8 pCasper cells. Scale bars are 20 μm. K) Quantification of ADCC of sorted cells from four patients at different stages of therapy. HR hazard ratio; CI confidence interval; In Kaplan-Meier survival curves black marks represent censored patients; ns non-significant; * p < 0.05; *** p < 0.001; **** p < 0.0001